The Complex Role of Gut Microbiota in Systemic Lupus Erythematosus and Lupus Nephritis: From Pathogenetic Factor to Therapeutic Target
Microorganisms,
Год журнала:
2025,
Номер
13(2), С. 445 - 445
Опубликована: Фев. 18, 2025
The
role
of
gut
microbiota
(GM)
and
intestinal
dysbiosis
in
triggering
the
onset
and/or
modulating
severity
progression
lupus
nephritis
(LN)
has
been
object
intense
research
over
last
few
years.
Some
alterations
at
phyla
level,
such
as
abundance
Proteobacteria
reduction
Firmicutes/Bacteroidetes
(F/B)
ratio
α-diversity
have
consistently
reported
systemic
erythematosus
(SLE),
whereas
a
more
specific
ascribed
to
some
species
(Bacteroides
thetaiotaomicron
Ruminococcus
gnavus)
LN.
Underlying
mechanisms
include
microbial
translocation
through
"leaky
gut"
subsequent
molecular
mimicry,
immune
dysregulation
(alteration
IFNγ
levels
balance
between
Treg
Th17
subsets),
epigenetic
interactions.
Levels
bacterial
metabolites,
butyrate
other
short-chain
fatty
acids
(SCFAs),
appear
play
key
Beyond
components
GM,
virome
mycobiome
are
also
increasingly
recognized
important
players
modulation
an
response.
On
hand,
microbiota-based
therapy
appears
promising
includes
diet,
prebiotics,
probiotics,
symbiotics,
fecal
transplantation
(FMT).
could
correct
critical
alterations,
F/B
Treg/Th17
imbalance,
blunt
production
autoantibodies
renal
damage.
Despite
current
limits,
GM
is
emerging
powerful
environmental
factor
that
be
harnessed
interfere
with
leading
SLE,
preventing
flares
organ
damage,
including
aim
this
review
provide
state-of-the-art
analysis
SLE
LN
on
one
while
exploring
possible
therapeutic
manipulation
control
disease
hand.
Язык: Английский
Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Март 17, 2025
Antimicrobial
resistance
(AMR)
has
become
a
major
and
escalating
global
health
threat,
undermining
the
effectiveness
of
current
antibiotic
antimicrobial
therapies.
The
rise
multidrug-resistant
bacteria
led
to
increasingly
difficult-to-treat
infections,
resulting
in
higher
morbidity,
mortality,
healthcare
costs.
Tackling
this
crisis
requires
development
novel
agents,
optimization
therapeutic
strategies,
initiatives
infection
surveillance
control.
Recent
studies
highlight
crucial
role
human
gut
microbiota
defending
against
AMR
pathogens.
A
balanced
protects
body
through
mechanisms
such
as
colonization
resistance,
positioning
it
key
ally
fight
AMR.
In
contrast,
dysbiosis
disrupts
defense,
thereby
facilitating
persistence,
colonization,
dissemination
resistant
This
review
will
explore
how
influence
drug-resistant
bacterial
its
involvement
various
types
AMR-related
potential
for
microbiota-targeted
therapies,
fecal
transplantation,
prebiotics,
probiotics,
phage
therapy.
Elucidating
interactions
between
pathogens
provide
critical
insights
developing
strategies
prevent
treat
infections.
While
previous
reviews
have
focused
on
general
impact
health,
specifically
look
at
latest
research
evolution
spread
AMR,
highlighting
strategies.
Язык: Английский
Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: from pathogenesis to efficacy
Therapeutic Advances in Gastroenterology,
Год журнала:
2025,
Номер
18
Опубликована: Янв. 1, 2025
Colorectal
cancer
(CRC)
remains
a
leading
cause
of
cancer-related
deaths
worldwide,
with
its
progression
intricately
linked
to
gut
microbiota
dysbiosis.
Disruptions
in
microbial
homeostasis
contribute
tumor
initiation,
immune
suppression,
and
inflammation,
establishing
the
as
key
therapeutic
target.
Fecal
transplantation
(FMT)
has
emerged
transformative
approach
restore
balance,
enhance
responses,
reshape
microenvironment.
This
review
explores
mechanisms
underlying
FMT’s
potential,
evaluates
advantages
over
other
microbiota-based
interventions,
addresses
challenges
such
donor
selection,
safety
concerns,
treatment
standardization.
Looking
forward,
integration
FMT
into
personalized
CRC
therapies
requires
robust
clinical
trials
identification
predictive
biomarkers
optimize
efficacy
safety.
Язык: Английский
Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay
Frontiers in Microbiology,
Год журнала:
2025,
Номер
16
Опубликована: Март 25, 2025
Fecal
microbiota
transplantation
(FMT)
represents
a
therapeutic
approach
that
directly
regulates
the
gut
of
recipients,
normalizes
its
composition
and
reaping
rewards.
Currently,
in
addition
to
general
application
treating
Clostridium
difficile
(
C.
)
infection
(CDI),
FMT
treatment
has
also
been
extended
fields
other
gastrointestinal
diseases,
infections,
gut-liver
or
gut-brain
axis
disorders,
metabolic
diseases
cancer,
etc.
Prior
FMT,
rigorous
donor
screening
is
essential
reduce
occurrence
adverse
events.
In
addition,
it
imperative
evaluate
whether
recipient
can
safely
effectively
undergo
treatment.
However,
efficacy
influenced
by
complex
interactions
between
recipient,
degree
engraftment
not
necessarily
positively
related
with
success
rate
FMT.
Furthermore,
an
increasing
number
novel
factors
affecting
outcomes
are
being
identified
recent
clinical
trials
animal
experiments,
broadening
our
understanding
This
article
provides
comprehensive
review
scenarios
influencing
safety
from
aspects
both
donors
summarizes
how
these
emerging
regulatory
be
combined
predict
patients
undergoing
Язык: Английский
Fecal microbiota transplantation: a tale of two regulatory pathways
Gut Microbes,
Год журнала:
2025,
Номер
17(1)
Опубликована: Апрель 29, 2025
Fecal
microbiota
transplantation
(FMT)
is
a
procedure
involving
the
transfer
of
intestinal
from
healthy
donor
to
patient
restore
functional
microbiome.
First
described
in
modern
science
1958,
use
FMT
has
been
practiced
for
decades,
but
only
during
past
dozen
years
have
clinical
frameworks
and
legal
regulations
competent
authorities
developed.
Future
development
microbiota-derived
medical
therapies
will
be
shaped
by
regulatory
various
jurisdictions.
This
review
examines
historical
status
United
States
Europe,
with
particular
attention
their
respective
approaches
ensuring
safety
quality
therapeutic
product
access.
Язык: Английский
IntestinalMicrobiota Transplant Prior toAllogeneicStem CellTransplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trial
BMJ Open,
Год журнала:
2024,
Номер
14(12), С. e093120 - e093120
Опубликована: Дек. 1, 2024
Introduction
Lower
diversity
of
the
gut
microbiome
prior
to
allogeneic
haematopoietic
cell
transplantation
(HCT)
correlates
with
reduced
survival
after
intervention.
Most
patients
undergoing
HCT
for
a
haematological
malignancy
have
previously
received
intensive
chemotherapy,
resulting
in
prolonged
neutropenic
episodes
requiring
broad-spectrum
antibiotics;
use
these
has
been
linked
diversity.
Intestinal
microbiota
transplant
(IMT)
is
novel
treatment
approach
that
restores
this
We
hypothesised
IMT
performed
initiation
conditioning
during
early
stages
HCT,
leading
decreased
frequency
complications
and
improved
outcomes
HCT.
Methods
analysis
50
adult
receiving
will
be
recruited
into
phase
IIa
trial
randomised
1:1
receive
capsulised
or
matched
placebo
shortly
followed
up
12
months.
The
primary
outcome
assess
increase
alpha
between
pre-IMT
measured
at
~42
days
administration
(day
+28
HCT),
comparing
difference
compared
placebo.
Secondary
include
tolerability,
dynamics
metrics
taxonomy
over
all
time
points
assessed,
as
well
clinical
(including
burden
invasive
infections,
fever,
admission
care,
development
graft-vs-host
disease
mortality).
Ethics
dissemination
This
study
was
approved
by
UK
Research
Committee
(REC
reference:
23/NE/0105).
Dissemination
results
concert
patient
public
involvement
group
input
expected
primarily
via
abstract
presentation
conferences
manuscripts
peer-reviewed
journals.
Trial
registration
numbers
NCT6355583
;
EudraCT:
2022-003617-10.
Язык: Английский